ESTRO 2024 - Abstract Book

S833

Clinical - CNS

ESTRO 2024

Conclusion:

Our data from our real-world experience demonstrated that hypofractionation may be an effective and safe option for patients with glioblastoma even more when associated with concurrent temozolamide in a wide range of patients. From our experience, this treatment is also well tolerated with low prevalence of toxicities. Further prospective studies may be necessary in order to better understand and standardize which patients most benefit from this fractionation.

Keywords: Glioblastoma, Dose fractionation, Survival

1281

Digital Poster

Repeated monosicentric-SRS for brain metastases and dosimetric analysis of recurrence pattern